){kind=logo}
Represented Titan Pharmaceuticals, Inc., in a licensing agreement with Braeburn Pharmaceuticals Sprl for U.S. and Canadian commercialization rights to Titan’s Probuphine® product, which is under review by the FDA.
Represented Titan Pharmaceuticals, Inc., in a licensing agreement with Braeburn Pharmaceuticals Sprl for U.S. and Canadian commercialization rights to Titan’s opioid addiction product Probuphine®, which is under review by the U.S. Food and Drug Administration (FDA). Under the terms of the deal, Titan received $15.75 million up-front and will receive up to an additional $215 million if Probuphine® is approved by the FDA and reaches sales and regulatory milestones.
-
合伙人